Skip to nav Skip to content
Jeffrey  West

Jeffrey West, PhD

Program: Integrated Mathematical Oncology

Research Program: Cancer Biology & Evolution Program

View Lab Page

Google Scholar Profile

Contact

  • Overview

    Studying the dynamics of cell-cell interactions that influence tumor evolution, heterogeneity, and treatment resistance.

    Associations

    • Integrated Mathematical Oncology
    • Cancer Biology & Evolution Program

    Education & Training

    Graduate:

    • University of Southern California, PhD - Aerospace & Mechanical Engineering

    Fellowship:

    • H. Lee Moffitt Cancer Center & Research Institute - Integrated Mathematical Oncology
  • Research Interest

    The goal of Dr. West’s research group is to aid in targeting treatment resistance by constructing mathematical models of 1) tumor evolution and heterogeneity and 2) evolutionary-minded treatment strategies, employing techniques such as agent-based modeling, dose response convexity analysis (second-order effects), and evolutionary game theory. These methods are broadly applicable to many cancer types, but recent publications have focused on applications to breast and prostate cancer.

  • Publications

    • West J, Rentzeperis F, Adam C, Bravo R, Luddy KA, Robertson-Tessi M, Anderson ARA. Tumor-immune metaphenotypes orchestrate an evolutionary bottleneck that promotes metabolic transformation. Front Immunol. 2024 Feb.15:1323319. Pubmedid: 38426105. Pmcid: PMC10902449.
    • Marzban S, Srivastava S, Kartika S, Bravo R, Safriel R, Zarski A, Anderson A, Chung CH, Amelio AL, West J. Spatial interactions modulate tumor growth and immune infiltration. bioRxiv. 2024 Feb. Pubmedid: 38370722. Pmcid: PMC10871273.
    • Gillis N, Padron E, Wang T, Chen K, DeVos JD, Spellman SR, Lee SJ, Kitko CL, MacMillan ML, West J, Tang YH, Teng M, McNulty S, Druley TE, Pidala JA, Lazaryan A. Pilot Study of Donor-Engrafted Clonal Hematopoiesis Evolution and Clinical Outcomes in Allogeneic Hematopoietic Cell Transplantation Recipients Using a National Registry. Transplant Cell Ther. 2023 Oct.29(10):640.e1-640.e8. Pubmedid: 37517612. Pmcid: PMC10592088.
    • Strobl MAR, Gallaher J, Robertson-Tessi M, West J, Anderson ARA. Treatment of evolving cancers will require dynamic decision support. Ann Oncol. 2023 Oct.34(10):867-884. Pubmedid: 37777307.
    • West J, Adler F, Gallaher J, Strobl M, Brady-Nicholls R, Brown J, Robertson-Tessi M, Kim E, Noble R, Viossat Y, Basanta D, Anderson ARA. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation. Elife. 2023 Mar.12. Pubmedid: 36952376. Pmcid: PMC10036119.
    • Strobl M, Martin AL, West J, Gallaher J, Robertson-Tessi M, Gatenby R, Wenham R, Maini P, Damaghi M, Anderson A. Adaptive therapy for ovarian cancer: An integrated approach to PARP inhibitor scheduling. bioRxiv. 2023 Mar. Pubmedid: 36993591. Pmcid: PMC10055330.
    • Taleb NN, West J. Working with Convex Responses: Antifragility from Finance to Oncology. Entropy (Basel). 2023 Feb.25(2). Pubmedid: 36832709. Pmcid: PMC9955868.
    • Axenie C, López-Corona O, Makridis MA, Akbarzadeh M, Saveriano M, Stancu A, West J. Antifragility as a complex system's response to perturbations, volatility, and time. ArXiv. 2023 Dec. Pubmedid: 38196741. Pmcid: PMC10775345.
    • Gallaher J, Strobl M, West J, Gatenby R, Zhang J, Robertson-Tessi M, Anderson ARA. Intermetastatic and Intrametastatic Heterogeneity Shapes Adaptive Therapy Cycling Dynamics. Cancer Res. 2023 Aug.83(16):2775-2789. Pubmedid: 37205789. Pmcid: PMC10425736.
    • West J, Robertson-Tessi M, Anderson ARA. Agent-based methods facilitate integrative science in cancer. Trends Cell Biol. 2023 Apr.33(4):300-311. Pubmedid: 36404257.
    • Prabhakaran S, Gatenbee C, Robertson-Tessi M, West J, Beg AA, Gray J, Antonia S, Gatenby RA, Anderson ARA. Mistic: An open-source multiplexed image t-SNE viewer. Patterns (N Y). 2022 Jul.3(7):100523. Pubmedid: 35845830. Pmcid: PMC9278502.
    • Schenck RO, Kim E, Bravo RR, West J, Leedham S, Shibata D, Anderson ARA. Homeostasis limits keratinocyte evolution. Proc Natl Acad Sci U S A. 2022 Aug.119(35). Pubmedid: 35998218. Pmcid: PMC9436311.
    • Schenck RO, Brosula G, West J, Leedham S, Shibata D, Anderson AR. Gattaca: Base-Pair Resolution Mutation Tracking for Somatic Evolution Studies using Agent-based Models. Mol Biol Evol. 2022 Apr.39(4). Pubmedid: 35298641. Pmcid: PMC9034688.
    • Strobl MAR, Gallaher J, West J, Robertson-Tessi M, Maini PK, Anderson ARA. Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. Commun Med (Lond). 2022 Apr.2:46. Pubmedid: 35603284. Pmcid: PMC9053239.
    • Gatenbee CD, Baker AM, Schenck RO, Strobl M, West J, Neves MP, Hasan SY, Lakatos E, Martinez P, Cross WCH, Jansen M, Rodriguez-Justo M, Whelan CJ, Sottoriva A, Leedham S, Robertson-Tessi M, Graham TA, Anderson ARA. Immunosuppressive niche engineering at the onset of human colorectal cancer. Nat Commun. 2022 Apr.13(1):1798. Pubmedid: 35379804. Pmcid: PMC8979971.
    • Damaghi M, West J, Robertson-Tessi M, Xu L, Ferrall-Fairbanks MC, Stewart PA, Persi E, Fridley BL, Altrock PM, Gatenby RA, Sims PA, Anderson ARA, Gillies RJ. The harsh microenvironment in early breast cancer selects for a Warburg phenotype. Proc Natl Acad Sci U S A. 2021 Jan.118(3). Pubmedid: 33452133. Pmcid: PMC7826394.
    • Strobl MAR, West J, Viossat Y, Damaghi M, Robertson-Tessi M, Brown JS, Gatenby RA, Maini PK, Anderson ARA. Turnover Modulates the Need for a Cost of Resistance in Adaptive Therapy. Cancer Res. 2021 Feb.81(4):1135-1147. Pubmedid: 33172930. Pmcid: PMC8455086.
    • West J, Schenck RO, Gatenbee C, Robertson-Tessi M, Anderson ARA. Normal tissue architecture determines the evolutionary course of cancer. Nat Commun. 2021 Apr.12(1):2060. Pubmedid: 33824323. Pmcid: PMC8024392.
    • Bravo RR, Baratchart E, West J, Schenck RO, Miller AK, Gallaher J, Gatenbee CD, Basanta D, Robertson-Tessi M, Anderson ARA. Hybrid Automata Library: A flexible platform for hybrid modeling with real-time visualization. PLoS Comput Biol. 2020 Mar.16(3):e1007635. Pubmedid: 32155140. Pmcid: PMC7105119.
    • West J, Ma Y, Kaznatcheev A, Anderson ARA. IsoMaTrix: a framework to visualize the isoclines of matrix games and quantify uncertainty in structured populations. Bioinformatics. 2020 Dec. Pubmedid: 33325501. Pmcid: PMC8016459.
    • West J, You L, Zhang J, Gatenby RA, Brown JS, Newton PK, Anderson ARA. Towards Multidrug Adaptive Therapy. Cancer Res. 2020 Apr.80(7):1578-1589. Pubmedid: 31948939. Pmcid: PMC7307613.
    • West JB, Dinh MN, Brown JS, Zhang J, Anderson AR, Gatenby RA. Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy. Clin Cancer Res. 2019 Jul.25(14):4413-4421. Pubmedid: 30992299. Pmcid: PMC6665681.
    • West J, Robertson-Tessi M, Luddy K, Park DS, Williamson DFK, Harmon C, Khong HT, Brown J, Anderson ARA. The Immune Checkpoint Kick Start: Optimization of Neoadjuvant Combination Therapy Using Game Theory. JCO Clin Cancer Inform. 2019 Feb.3:1-12. Pubmedid: 30742484. Pmcid: PMC6873943.
    • West J, Newton PK. Cellular interactions constrain tumor growth. Proc Natl Acad Sci U S A. 2019 Feb.116(6):1918-1923. Pubmedid: 30674661. Pmcid: PMC6369808.
    • West J, Ma Y, Newton PK. Capitalizing on competition: An evolutionary model of competitive release in metastatic castration resistant prostate cancer treatment. J Theor Biol. 2018 Oct.455:249-260. Pubmedid: 30048718. Pmcid: PMC7519622.
    • West J, Hasnain Z, Macklin P, Newton PK. AN EVOLUTIONARY MODEL OF TUMOR CELL KINETICS AND THE EMERGENCE OF MOLECULAR HETEROGENEITY DRIVING GOMPERTZIAN GROWTH. SIAM Rev Soc Ind Appl Math. 2018 Jun.58(4):716-736. Pubmedid: 29937592. Pmcid: PMC6013275.
    • West J, Newton PK. Chemotherapeutic Dose Scheduling Based on Tumor Growth Rates Provides a Case for Low-Dose Metronomic High-Entropy Therapies. Cancer Res. 2017 Dec.77(23):6717-6728. Pubmedid: 28986381. Pmcid: PMC5712269.
    • West J, Hasnain Z, Mason J, Newton PK. The prisoner's dilemma as a cancer model. Converg Sci Phys Oncol. 2016 Sep.2(3). Pubmedid: 29177084. Pmcid: PMC5701760.
  • Grants

    • Title: Virtual patient cohort generation for radiation therapy using probability distribution convolution
      Sponsor: Moffitt Cancer Center
      PI: West, J.
    • Title: Evolutionary Therapy in ER+ Breast Cancer Guided by Second-Order Reasoning
      Sponsor: Moffitt Cancer Center
      PI: West, J.

Find a Researcher Search